Find out how Wegovy® pen, along with a reduced-calorie diet and increased physical activity, can help adults with obesity, or with overweight and at least one weight-related medical problem lose weight and keep it off.
Information on this page:
In a 68-week medical study: Adults with obesity, or with overweight and at least one weight-related medical problem, who used Wegovy® pen, along with diet and exercise, lost an average 35 lb. Everyone was instructed to follow a reduced-calorie diet and increase their physical activity.
Adults who used Wegovy® pen achieved on average 15% weight loss
~35 lb
232 lb starting weight
Adults who used placebo achieved on average ~2.5% weight loss
~6 lb
232 lb starting weight
83% (~8 in 10) of adults using Wegovy® pen lost 5% or more weight compared with 31% taking placebo, 66% (~6 in 10) of adults using Wegovy® pen lost 10% or more weight compared with 12% taking placebo, and 48% (~5 in 10) of adults using Wegovy® pen lost 15% or more weight compared with 5% taking placebo.
In the same study
About 1 in 3 adults achieved 20% weight loss ~46 lb based on 232 lb starting weight
30% of adults (about 1 in 3) taking Wegovy® lost 20% or more weight compared with 2% of adults on placebo.
This result was not the primary goal of the study and should be considered as additional information. Individual results may vary.
Results are from a 68-week medical study of 1,961 adults with obesity (BMI >=30 kg/m2), or with overweight (BMI >=27 kg/m2) and at least one weight-related medical problem, including high blood pressure or high cholesterol. Adults with type 2 diabetes were excluded. Patients were taking either Wegovy pen or placebo. Both groups received instruction for a reduced calorie diet and increased physical activity. During the trial, 17% of participants taking Wegovy discontinued treatment compared with 22% taking placebo.
BMI=body mass index.
Learn more about Wegovy® pen for weight loss
Remember, if it's not made by Novo Nordisk®, it’s not FDA-approved Wegovy®.
Your healthcare professional will determine the right dose of the pen and make any needed adjustments. Always follow the detailed instructions provided by your healthcare professional and in the Instructions for Use, including specific timing and food considerations.
FDA=Food and Drug Administration.
FAQs about Wegovy® pen
In a medical study, adults living with obesity, or with overweight and at least one weight-related medical problem, who used Wegovy® pen, along with a reduced-calorie diet and increased physical activity, lost on average about 35 lb, which was about 15% of their starting body weight. In comparison, adults who used placebo lost on average about 6 lb, or about 2.5% of their body weight. The average starting weight for both groups was 232 lb.
83% or about 8 in 10 adults achieved 5% or more weight loss with Wegovy® compared with 31% taking placebo.
Results are from a 68-week medical study of 1,961 adults with obesity (BMI >=30 kg/m2), or with overweight (BMI >=27 kg/m2) and at least one weight-related medical problem, including high blood pressure or high cholesterol. Adults with type 2 diabetes were excluded. Patients were taking either Wegovy® pen or placebo. Both groups received instruction for a reduced calorie diet and increased physical activity. During the trial, 17% of participants taking Wegovy® discontinued treatment compared with 22% taking placebo.
BMI=body mass index.
In a medical study, adults living with obesity, or with overweight and at least one weight-related medical problem, who used the Wegovy® pen, along with a reduced-calorie diet and increased physical activity, lost on average about 35 lb which was about 15% of their starting body weight. In comparison, adults who used placebo lost on average about 6 lb, or about 2.5% of their body weight. The average starting weight for both groups was 232 lb. Use the weight loss calculator to get an idea of how much you could potentially lose with Wegovy®.
83% or about 8 in 10 adults achieved 5% or more weight loss with Wegovy® compared with 31% taking placebo.
Results are from a 68-week medical study of 1,961 adults with obesity (BMI ≥30) and adults with overweight (BMI ≥27) who also had weight-related medical problems, including high blood pressure or high cholesterol. Adults with diabetes were excluded. Both groups received instruction for a reduced-calorie diet and increased physical activity. During the trial, 17% of participants taking Wegovy® discontinued treatment compared with 22% taking placebo.
BMI=body mass index.
People respond to medication, including Wegovy®, differently, so there is no set time when you can expect to see results with Wegovy®. Ask your healthcare professional about what might be realistic for you.
Become a WEGOVY® INSIDER
Get the latest news about managing weight with Wegovy®.
Wegovy® may cause serious side effects, including:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Wegovy® may affect the way some medicines work and some medicines may affect the way Wegovy® works. Tell your healthcare provider if you are taking other medicines to treat diabetes, including sulfonylureas or insulin. Wegovy® slows stomach emptying and can affect medicines that need to pass through the stomach quickly.
Wegovy® may cause serious side effects, including:
The most common side effects of Wegovy® may include: nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and runny nose or sore throat.
Please see Prescribing Information and Medication Guide for Wegovy®.
Wegovy® is a prescription medication.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
This site is intended for US patients only.
Wegovy® (semaglutide) injection 1.7 mg or 2.4 mg and Wegovy® (semaglutide) tablets 25 mg are prescription medicines used with a reduced calorie diet and increased physical activity to:
Wegovy® (semaglutide) injection 1.7 mg or 2.4 mg is used with a reduced-calorie diet and increased physical activity to help children 12 years and older with obesity to lose weight and keep the weight off
Wegovy® contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines.
It is not known if Wegovy® injection is safe and effective:
It is not known if Wegovy® tablets are safe and effective for use in people under 18 years of age.
Wegovy® (semaglutide) injection 1.7 mg or 2.4 mg and Wegovy® (semaglutide) tablets 25 mg are prescription medicines used with a reduced calorie diet and increased physical activity to:
Wegovy® (semaglutide) injection 1.7 mg or 2.4 mg is used with a reduced-calorie diet and increased physical activity to help children 12 years and older with obesity to lose weight and keep the weight off
Wegovy® contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines.
It is not known if Wegovy® injection is safe and effective:
It is not known if Wegovy® tablets are safe and effective for use in people under 18 years of age.
Wegovy® may cause serious side effects, including:
Wegovy® may cause serious side effects, including:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Wegovy® may affect the way some medicines work and some medicines may affect the way Wegovy® works. Tell your healthcare provider if you are taking other medicines to treat diabetes, including sulfonylureas or insulin. Wegovy® slows stomach emptying and can affect medicines that need to pass through the stomach quickly.
Wegovy® may cause serious side effects, including:
The most common side effects of Wegovy® may include: nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and runny nose or sore throat.
Please see Prescribing Information and Medication Guide for Wegovy®.
Wegovy® is a prescription medication.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
This site is intended for US patients only.
Wegovy® (semaglutide) injection 1.7 mg or 2.4 mg and Wegovy® (semaglutide) tablets 25 mg are prescription medicines used with a reduced calorie diet and increased physical activity to:
Wegovy® (semaglutide) injection 1.7 mg or 2.4 mg is used with a reduced-calorie diet and increased physical activity to help children 12 years and older with obesity to lose weight and keep the weight off
Wegovy® contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines.
It is not known if Wegovy® injection is safe and effective:
It is not known if Wegovy® tablets are safe and effective for use in people under 18 years of age.